Liraglutide vs GHRP-6
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss AgonistsFat Loss & Metabolic
LiraglutideGrowth Hormone Peptides
GHRP-6- Summary
- Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
- GHRP-6 is the original synthetic GH-releasing peptide and a potent ghrelin receptor agonist. It produces strong GH pulses but is notorious for a significant hunger surge 30–45 minutes post-injection. This hunger side effect makes it less preferred than Ipamorelin or GHRP-2 for most protocols but can be useful in patients with appetite deficiency.
- Half-Life
- ~13 hours (once-daily dosing)
- 15–60 minutes
- Admin Route
- SubQ
- SubQ, Intranasal
- Research
- —
- —
- Typical Dose
- Start 0.6 mg, titrate to 3 mg
- 100–300 mcg
- Frequency
- Once daily
- 2–3 times daily
- Key Benefits
- Promotes weight loss (5–10% average)
- Reduces appetite and caloric intake
- Improves blood glucose control (HbA1c reduction)
- Reduces cardiovascular events in T2DM (LEADER trial)
- Slows gastric emptying
- FDA-approved for T2DM and chronic weight management
- Cardioprotective effects shown in clinical trials
- May improve fatty liver (NAFLD/NASH)
- Strong GH stimulation
- Elevated IGF-1
- Muscle growth and recovery support
- Potential anti-inflammatory effects at GI level
- Useful for patients with appetite deficiency or cachexia
- Enhanced recovery from training
- Side Effects
- Nausea (very common, especially initially)
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- +5 more
- Intense hunger surge (30–45 min post-injection)
- Water retention
- Elevated cortisol (modest)
- Elevated prolactin (modest)
- +2 more
- Stacks With
- —
- —